7 reports of this reaction
1.6% of all FLUPHENAZINE HYDROCHLORIDE reports
#18 most reported adverse reaction
ANOSOGNOSIA is the #18 most commonly reported adverse reaction for FLUPHENAZINE HYDROCHLORIDE, manufactured by Rising Pharma Holdings, Inc.. There are 7 FDA adverse event reports linking FLUPHENAZINE HYDROCHLORIDE to ANOSOGNOSIA. This represents approximately 1.6% of all 426 adverse event reports for this drug.
Patients taking FLUPHENAZINE HYDROCHLORIDE who experience anosognosia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANOSOGNOSIA is a less commonly reported adverse event for FLUPHENAZINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to anosognosia, the following adverse reactions have been reported for FLUPHENAZINE HYDROCHLORIDE:
The following drugs have also been linked to anosognosia in FDA adverse event reports:
ANOSOGNOSIA has been reported as an adverse event in 7 FDA reports for FLUPHENAZINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANOSOGNOSIA accounts for approximately 1.6% of all adverse event reports for FLUPHENAZINE HYDROCHLORIDE, making it a notable side effect.
If you experience anosognosia while taking FLUPHENAZINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.